Your browser doesn't support javascript.
Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021.
Mateo-Urdiales, Alberto; Spila Alegiani, Stefania; Fabiani, Massimo; Pezzotti, Patrizio; Filia, Antonietta; Massari, Marco; Riccardo, Flavia; Tallon, Marco; Proietti, Valeria; Del Manso, Martina; Puopolo, Maria; Spuri, Matteo; Morciano, Cristina; D'Ancona, Fortunato Paolo; Da Cas, Roberto; Battilomo, Serena; Bella, Antonino; Menniti-Ippolito, Francesca.
  • Mateo-Urdiales A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Spila Alegiani S; European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Fabiani M; National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Pezzotti P; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Filia A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Massari M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Riccardo F; National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Tallon M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Proietti V; Department of Informatics, Istituto Superiore di Sanità, Rome, Italy.
  • Del Manso M; DG-SISS, Ministero della Salute, Rome, Italy.
  • Puopolo M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Spuri M; European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Morciano C; Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
  • D'Ancona FP; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Da Cas R; Research Coordination and Support Service, Istituto Superiore di Sanità, Rome, Italy.
  • Battilomo S; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Bella A; National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Menniti-Ippolito F; DG-SISS, Ministero della Salute, Rome, Italy.
Euro Surveill ; 26(25)2021 Jun.
Article in English | MEDLINE | ID: covidwho-1288763
ABSTRACT
To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0-14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR) 0.22; 95% CI 0.21-0.24) 43-49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR 0.11; 95% CI 0.09-0.15) and 93% (IRR 0.07; 95% CI 0.04-0.11) reductions 36-42 days post-first dose. Our results support ongoing vaccination campaigns.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.25.2100507

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.25.2100507